IL158246A0 - Immunotherapeutic combinations for the treatment of tumours that overexpress gangliosides - Google Patents

Immunotherapeutic combinations for the treatment of tumours that overexpress gangliosides

Info

Publication number
IL158246A0
IL158246A0 IL15824602A IL15824602A IL158246A0 IL 158246 A0 IL158246 A0 IL 158246A0 IL 15824602 A IL15824602 A IL 15824602A IL 15824602 A IL15824602 A IL 15824602A IL 158246 A0 IL158246 A0 IL 158246A0
Authority
IL
Israel
Prior art keywords
tumours
treatment
immunotherapeutic combinations
gangliosides
overexpress
Prior art date
Application number
IL15824602A
Other languages
English (en)
Original Assignee
Centro Inmunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro Inmunologia Molecular filed Critical Centro Inmunologia Molecular
Publication of IL158246A0 publication Critical patent/IL158246A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/739—Lipopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/001171—Gangliosides, e.g. GM2, GD2 or GD3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • C07K16/4266—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig against anti-tumor receptor Ig
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C12N5/0694—Cells of blood, e.g. leukemia cells, myeloma cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/686—Anti-idiotype
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7023—(Hyper)proliferation
    • G01N2800/7028—Cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL15824602A 2001-04-06 2002-04-08 Immunotherapeutic combinations for the treatment of tumours that overexpress gangliosides IL158246A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU2001008420010084A CU23007A1 (es) 2001-04-06 2001-04-06 Combinaciones inmunoterapéuticas para el tratamiencombinaciones inmunoterapéuticas para el tratamiento de tumores que sobre-expresan gangliósidos to de tumores que sobre-expresan gangliósidos
PCT/CU2002/000002 WO2002081661A2 (fr) 2001-04-06 2002-04-08 Combinaisons immunotherapeutiques utilisees dans le traitement de tumeurs surexprimant les gangliosides

Publications (1)

Publication Number Publication Date
IL158246A0 true IL158246A0 (en) 2004-05-12

Family

ID=40291118

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15824602A IL158246A0 (en) 2001-04-06 2002-04-08 Immunotherapeutic combinations for the treatment of tumours that overexpress gangliosides
IL158246A IL158246A (en) 2001-04-06 2003-10-02 Pharmaceutical compositions for the treatment of tumours that overexpress gangliosides and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL158246A IL158246A (en) 2001-04-06 2003-10-02 Pharmaceutical compositions for the treatment of tumours that overexpress gangliosides and uses thereof

Country Status (36)

Country Link
US (3) US20040253233A1 (fr)
EP (3) EP1798243B1 (fr)
JP (2) JP2004528033A (fr)
KR (3) KR100946168B1 (fr)
CN (3) CN1319991C (fr)
AR (2) AR033123A1 (fr)
AT (3) ATE406386T1 (fr)
AU (3) AU2002308347B2 (fr)
BG (2) BG66304B1 (fr)
BR (3) BR0208675A (fr)
CA (2) CA2441845C (fr)
CU (1) CU23007A1 (fr)
CZ (2) CZ296276B6 (fr)
DE (2) DE60228561D1 (fr)
DK (2) DK1411064T3 (fr)
EA (2) EA006936B1 (fr)
EC (2) ECSP034788A (fr)
ES (2) ES2312610T3 (fr)
HR (2) HRP20030805B1 (fr)
HU (2) HU228106B1 (fr)
IL (2) IL158246A0 (fr)
IS (2) IS2701B (fr)
MX (2) MXPA03008738A (fr)
MY (3) MY137078A (fr)
NO (2) NO20034437L (fr)
NZ (2) NZ528598A (fr)
PE (1) PE20020972A1 (fr)
PL (2) PL208109B1 (fr)
PT (2) PT1411064E (fr)
SG (1) SG161737A1 (fr)
SI (2) SI1411064T1 (fr)
SK (2) SK287783B6 (fr)
UA (3) UA75393C2 (fr)
UY (2) UY27242A1 (fr)
WO (2) WO2002081661A2 (fr)
ZA (2) ZA200307585B (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7297336B2 (en) * 2003-09-12 2007-11-20 Baxter International Inc. Factor IXa specific antibodies displaying factor VIIIa like activity
CN103143004A (zh) * 2005-02-04 2013-06-12 萨瓦克公司 存活蛋白肽疫苗
FI20055398A0 (fi) * 2005-07-08 2005-07-08 Suomen Punainen Risti Veripalv Menetelmä solupopulaatioiden evaluoimiseksi
CA2618796C (fr) * 2005-08-11 2018-01-02 Arpi Matossian-Rogers Peptides pour traitement et diagnostic d'une maladie auto-immune
ES2534760T3 (es) 2005-08-19 2015-04-28 Wyeth Llc Anticuerpos antagonistas contra GDF-8 y sus usos en el tratamiento de ELA y otros trastornos asociados con GDF-8
ITFI20060163A1 (it) * 2006-06-29 2006-09-28 Menarini Internat Operations Luxembourg Sa Composizione farmaceutica contenente un anticorpo monoclonale anti idiotipico anti-ca-125 ed alluminio
TWI434855B (zh) 2006-11-21 2014-04-21 Hoffmann La Roche 結合物及其在免疫分析中作為參考標準之用途
JP5465542B2 (ja) * 2008-02-22 2014-04-09 片山化学工業株式会社 合成糖脂質含有リポソーム
EP2166085A1 (fr) 2008-07-16 2010-03-24 Suomen Punainen Risti Veripalvelu Cellules modifiées bivalentes
TWI516501B (zh) 2008-09-12 2016-01-11 禮納特神經系統科學公司 Ｐｃｓｋ９拮抗劑類
EP2406284B9 (fr) * 2009-03-10 2017-03-01 Biogen MA Inc. Anticorps anti-bcma
WO2010120561A1 (fr) * 2009-04-01 2010-10-21 Genentech, Inc. Anticorps et immunoconjugués anti-fcrh5 et procédés d'utilisation
CU23736A1 (es) * 2009-05-04 2011-11-15 Centro Inmunologia Molecular Anticuerpos que reconocen sulfatidos y proteoglicanos sulfatados y su uso
AU2010291835A1 (en) * 2009-09-03 2012-04-19 Vancouver Biotech Ltd. Monoclonal antibodies against gonadotropin-releasing hormone receptor
AU2012205663B2 (en) * 2011-01-10 2017-02-02 Emory University Antibodies directed against influenza
CU24070B1 (es) * 2011-12-27 2015-01-29 Ct De Inmunología Molecular Composiciones farmacéuticas para el tratamiento de tumores que expresan regf y gangliósidos n-glicolilados gm3 (neugcgm3)
EP2641916A1 (fr) * 2012-03-23 2013-09-25 Centre National de la Recherche Scientifique (C.N.R.S) Nouveaux anticorps anti sPLA2-IIA et leurs utilisations
EP2861617A1 (fr) 2012-06-15 2015-04-22 Pfizer Inc. Anticorps antagonistes améliorés dirigés contre gdf-8 et leurs utilisations
TWI725931B (zh) 2013-06-24 2021-05-01 美商建南德克公司 抗ｆｃｒｈ５抗體
UA129760C2 (uk) 2013-12-17 2025-07-30 Дженентек, Інк. Анти-cd3 антитіло та спосіб його застосування
CA2941029C (fr) * 2014-04-10 2021-02-16 Obi Pharma Inc. Anticorps, compositions pharmaceutiques et leurs utilisations
TWI715587B (zh) 2015-05-28 2021-01-11 美商安可美德藥物股份有限公司 Ｔｉｇｉｔ結合劑和彼之用途
TWI731861B (zh) 2015-06-16 2021-07-01 美商建南德克公司 FcRH5之人源化及親和力成熟抗體及使用方法
WO2018017864A2 (fr) * 2016-07-20 2018-01-25 Oncomed Pharmaceuticals, Inc. Agents de liaison à pvrig et leurs utilisations
CN110662552A (zh) 2016-11-30 2020-01-07 昂科梅德制药有限公司 包含tigit结合剂的癌症治疗方法
CU20170173A7 (es) * 2017-12-27 2019-11-04 Ct Inmunologia Molecular Nano-partículas que contienen el gangliósido gm3 como inmunomoduladoras
IL299827B1 (en) 2020-07-15 2026-04-01 Cerebral Therapeutics Inc A medical system that includes two access ports
US12605537B2 (en) 2022-02-15 2026-04-21 Biogen Ma Inc. Implantable medical device for use with or having recording electrode

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2754206B2 (ja) * 1987-11-17 1998-05-20 メクト株式会社 α２→３結合を認識するモノクローナル抗体
US6051225A (en) * 1988-10-19 2000-04-18 The Dow Chemical Company Family of high affinity, modified antibodies for cancer treatment
DK0586002T3 (da) * 1992-08-18 2000-06-19 Centro Inmunologia Molecular Monoklonale antistoffer, som genkender epidermisvækstfaktor-receptoren, celler og fremgangsmåder heraf og præparater indeho
JPH07101999A (ja) * 1993-10-06 1995-04-18 Hagiwara Yoshihide 抗癌ヒトモノクローナル抗体に対する抗イデイオタイプ抗体のアミノ酸配列およびそれをコードするｄｎａ塩基配列
CA2137638C (fr) * 1993-12-09 1999-07-20 Ana M. V. Lopez Anticoprs monoclonaux antigangliosides et leur emploi dans l'immunotherapie active specifique a des tumeurs malignes
CU22702A1 (es) * 1997-10-21 2001-07-31 Centro Inmunologia Molecular Anticuerpos monoclonales anti - idiotipo, su uso en la inmunoterapia activa de tumores malignos, hibridoma que los produce y composiciones que los contienen
US6063379A (en) * 1993-12-09 2000-05-16 Centro De Inmunologia Molecular Anti-idiotypic monoclonal antibodies and compositions including the anti-idiotypic monoclonal antibodies
US6149921A (en) * 1993-12-29 2000-11-21 Centro De Inmunologia Molecular Vaccine compositions for eliciting an immune response against N-acetylated gangliosides and their use for cancer treatment
CU22420A1 (es) * 1993-12-29 1996-01-31 Centro Inmunologia Molecular Composicion vacunal para el desarrollo de una respuesta contra gangliosidos n glicolilados y su uso para el tratamiento del cancer
CU22615A1 (es) * 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
CU22731A1 (es) * 1998-02-05 2002-02-28 Centro Inmunologia Molecular Anticuerpo monoclonal que reconoce el oligosacárido ácido siálico n´glicolilado-galactosa-glucosa (ngcneu-gal-glu) en tumores malignos y composiciones farmacéuticas que los contienen
US7442776B2 (en) * 1999-10-08 2008-10-28 Young David S F Cancerous disease modifying antibodies

Also Published As

Publication number Publication date
BR0208676A (pt) 2008-04-08
HUP0401355A2 (hu) 2004-10-28
KR20080080680A (ko) 2008-09-04
HU228105B1 (en) 2012-11-28
HU228106B1 (en) 2012-11-28
ES2296986T3 (es) 2008-05-01
PE20020972A1 (es) 2003-01-02
US20050069535A1 (en) 2005-03-31
AU2007231687B2 (en) 2010-09-30
DE60223547T2 (de) 2008-09-18
ATE378356T1 (de) 2007-11-15
SI1411064T1 (sl) 2008-04-30
MY137078A (en) 2008-12-31
JP2004525953A (ja) 2004-08-26
IS6965A (is) 2003-09-23
KR100863509B1 (ko) 2008-10-15
BG66304B1 (bg) 2013-03-29
IS6964A (is) 2003-09-23
CZ20032668A3 (cs) 2004-07-14
WO2002081496A3 (fr) 2004-02-19
US20100297008A1 (en) 2010-11-25
CN1535282A (zh) 2004-10-06
MY157372A (en) 2016-06-15
AU2002308348B2 (en) 2007-11-22
BR0208675A (pt) 2004-08-03
DE60223547D1 (de) 2007-12-27
EA200301097A1 (ru) 2004-02-26
UA75393C2 (en) 2006-04-17
EA200301098A1 (ru) 2004-04-29
NO20034436D0 (no) 2003-10-03
PL208109B1 (pl) 2011-03-31
IS2701B (is) 2010-11-15
BR0208676B1 (pt) 2017-11-14
DK1411064T3 (da) 2008-03-25
IL158246A (en) 2010-05-31
EP1798243A2 (fr) 2007-06-20
WO2002081661A3 (fr) 2003-01-03
NO331533B1 (no) 2012-01-23
HK1070080A1 (zh) 2005-06-10
BG108228A (bg) 2005-04-30
US8758753B2 (en) 2014-06-24
ZA200307585B (en) 2004-09-16
ZA200307679B (en) 2005-03-30
UA86768C2 (ru) 2009-05-25
UY27242A1 (es) 2002-07-31
NO20034436L (no) 2003-12-02
SK12162003A3 (sk) 2004-05-04
KR20030087053A (ko) 2003-11-12
EP1411064A2 (fr) 2004-04-21
SK287783B6 (sk) 2011-09-05
CZ304424B6 (cs) 2014-04-30
EA006936B1 (ru) 2006-06-30
UY27243A1 (es) 2002-09-30
BRPI0208675B1 (pt) 2018-03-13
PL371770A1 (en) 2005-06-27
BG66293B1 (en) 2013-02-28
ES2312610T3 (es) 2009-03-01
HUP0401695A3 (en) 2012-05-29
AR033123A1 (es) 2003-12-03
NO20034437D0 (no) 2003-10-03
KR20030092048A (ko) 2003-12-03
CN101054417A (zh) 2007-10-17
EP1411064B1 (fr) 2007-11-14
KR100919617B1 (ko) 2009-09-29
CA2443372C (fr) 2013-05-28
CA2441845C (fr) 2011-06-07
EP1384726A2 (fr) 2004-01-28
JP2004528033A (ja) 2004-09-16
ECSP034787A (es) 2004-01-28
SG161737A1 (en) 2010-06-29
US20040253233A1 (en) 2004-12-16
EP1798243A3 (fr) 2007-10-17
MXPA03008738A (es) 2003-12-11
ATE406386T1 (de) 2008-09-15
SI1384726T1 (sl) 2009-04-30
HRP20030806B1 (hr) 2011-11-30
EP1798243B1 (fr) 2010-08-11
CZ296276B6 (cs) 2006-02-15
HUP0401695A2 (en) 2006-08-28
NO20034437L (no) 2003-12-02
HRP20030805A2 (en) 2005-08-31
ECSP034788A (es) 2004-01-28
CA2441845A1 (fr) 2002-10-17
HUP0401355A3 (en) 2012-05-29
PL371937A1 (en) 2005-07-11
SK287914B6 (sk) 2012-03-02
CA2443372A1 (fr) 2002-10-17
HK1066818A1 (en) 2005-04-01
HK1109160A1 (en) 2008-05-30
ATE477279T1 (de) 2010-08-15
DK1384726T3 (da) 2008-12-15
CU23007A1 (es) 2004-12-17
MY145703A (en) 2012-03-30
JP4366080B2 (ja) 2009-11-18
NZ528598A (en) 2005-03-24
CN100349920C (zh) 2007-11-21
SK12262003A3 (sk) 2004-08-03
UA76745C2 (uk) 2006-09-15
EP1384726B1 (fr) 2008-08-27
CN1507452A (zh) 2004-06-23
AU2002308347B2 (en) 2006-09-14
AU2007231687A1 (en) 2007-11-22
CZ20032641A3 (cs) 2004-07-14
CN101054417B (zh) 2012-07-11
WO2002081496A2 (fr) 2002-10-17
WO2002081661A2 (fr) 2002-10-17
HRP20030806A2 (en) 2005-08-31
EA006310B1 (ru) 2005-10-27
BG108227A (bg) 2005-04-30
PT1384726E (pt) 2008-12-05
DE60228561D1 (de) 2008-10-09
PT1411064E (pt) 2008-02-12
NZ528599A (en) 2005-03-24
KR100946168B1 (ko) 2010-03-11
MXPA03008739A (es) 2003-12-11
AR033122A1 (es) 2003-12-03
HRP20030805B1 (hr) 2011-11-30
CN1319991C (zh) 2007-06-06

Similar Documents

Publication Publication Date Title
HRP20030806A2 (en) Immunotherapeutic combinations for the treatment of tumours that overexpress gangliosides
AU2002308347A1 (en) Immunotherapeutic combinations for the treatment of tumours that overexpress gangliosides
IL251270A0 (en) Cancer treatment
IL164599A0 (en) Combination therapy for the treatment of cancer
ZA200408767B (en) Immunoconjugates for the treatment of tumours
HUP0400314A3 (en) Pharmaceutical combinations for the treatment of cancer
EP1463438A4 (fr) Therapie endomurale
HUP0500424A3 (en) Combination therapy for the treatment of cancer
IL158329A0 (en) Antiangiogenic combination therapy for the treatment of cancer
IL161267A0 (en) Combinations for the treatment of immunoinflammatory disorders
GB0126879D0 (en) Combination therapy
AU2152102A (en) Immunotherapeutic combinations for the treatment of tumors
AU2002221521A1 (en) Immunotherapeutic combinations for the treatment of tumors
IL162818A0 (en) Combination therapy for the treatment of bacterialinfections
GB0108485D0 (en) Combination therapy
AU2002304883A1 (en) Device for the treatment of tumours
HU0200253D0 (en) Combination therapy
EP1463511A4 (fr) Therapie anticancereuse combinatoire
GB0115870D0 (en) Tumour therapy
ZA200408071B (en) Combination therapy for the treatment of cancer.
GC0000285A (en) Herbal composition for the treatment of skin disorder
GB0118057D0 (en) The cancer medicine invention
GB0124029D0 (en) Combination therapy
ZA200306403B (en) Cancer treatment.